Crizotinib is an ATP-competitive small-molecule inhibitor of the receptor tyrosine kinases
(RTK) C-Met, ALK and ROS1. There is a robust effectiveness in non-small-cell lung cancer …

The NCI-MATCH was designed to characterize the efficacy of targeted therapies in histology-
agnostic driver mutation-positive malignancies. Sub-protocols F and G were developed to …

Crizotinib is an ATP-competitive small-molecule inhibitor of the receptor tyrosine kinases
(RTK) c-Met, anaplastic lymphoma kinase (ALK), and ROS1. There is convincing clinical …

Laryngeal squamous cell carcinoma (LSCC) is a common aggressive head and neck cancer
with high mortality and incidence. MicroRNAs (miRNAs) are short, non-coding and …

Chronic myelomonocytic leukemia (CMML) includes components of both myelodysplastic
syndrome and myeloproliferative neoplasms and is associated with a characteristic …

The evidence supporting the biological plausibility of the association of permethrin and
malathion with hematological cancer is limited and contradictory; thus, further studies are …

Background Despite targeted sequencing have identified several mutations for leukemia,
there is still a limit of mutation screening for Chinese leukemia. Here, we used targeted next …

The oncoprotein BCR-ABL1 triggers chronic myeloid leukemia. It is clear that the disease
relies on constitutive BCR-ABL1 kinase activity, but not all the interactors and regulators of …

Objective: Receptor tyrosine kinases (RTK) are relevant therapeutic targets in the treatment
of lung cancer. Germline susceptibility variants that influence these RTKs may provide new …

During the phase of proliferation needed for hematopoietic reconstitution following
transplantation, hematopoietic stem/progenitor cells (HSPC) must express genes involved in …